Single cell bar-coding for antibody discovery
Provided herein are methods and composition for immune repertoire sequencing and single cell barcoding. In some aspects, such methods may comprise steps of: (a) forming a plurality of first vessels each comprising: (i) a single cell, and (ii) a single solid support; (b) copying onto the single solid support: (i) a first copy of a first cell polynucleotide from the single cell, and (ii) a second copy of a second cell polynucleotide from the single cell; (c) forming a plurality of second vessels each comprising (i) a single solid support from the plurality of first vessels, and (ii) a barcoded polynucleotide; and (d) amplifying (i) the first copy and the second copy with a first primer set, and (ii) the barcode with a second primer set, wherein a primer of the first primer set is complementary to a primer of the second set; and (e) forming first and second single cell barcoded sequences.
1. A method comprising, in at least one vessel of a plurality of vessels, the at least one vessel comprising (i) an immune cell comprising an immunoglobulin heavy chain (IgH) mRNA and an immunoglobulin light chain (IgL) mRNA; (ii) a polynucleotide comprising a barcode, a first forward primer binding sequence, and a first reverse primer binding sequence; and (iii) a solid support comprising a polynucleotide complementary to at least a portion of the IgH mRNA and a polynucleotide complementary to at least a portion of the IgL mRNA:
(a) reverse transcribing the IgH and IgL mRNAs to form IgH and IgL cDNAs, wherein the IgH cDNA comprises a nucleic acid encoding a heavy chain variable region (VH) and the IgL cDNA comprises a nucleic acid encoding a light chain variable region (VL); wherein the IgH and IgL cDNAs comprise a second forward primer binding sequence and a sequence complementary to the first reverse primer binding sequence; and
(b) amplifying the IgH and IgL cDNAs, wherein the barcode is added to the IgH and IgL cDNAs using a first primer complementary to the first forward primer binding sequence, a second primer complementary to the second forward primer binding sequence, and a third primer complementary to the first reverse primer binding sequence;
wherein the method further comprises:
(c) sequencing the amplified barcoded IgH and IgL cDNAs, wherein sequencing the amplified barcoded IgH cDNAs occurs simultaneously with sequencing the amplified barcoded IgL cDNAs.
2. The method of claim 1 , further comprising selecting an antibody candidate based on:
(a) total quantity of two or more individually paired VH and VL sequences, and
(b) variance of the VH and/or VL sequence from a corresponding germ line sequence.
3. The method of claim 1 , wherein the immune cell is a leukocyte, B-cell, or T-cell.
4. The method of claim 1 , wherein the immune cell is a memory B-cell.
5. The method of claim 2 , further comprising screening the selected antibody for functional specificity, affinity, and/or neutralization ability.
6. The method of claim 2 , further comprising evolving the selected antibody by directed evolution.
7. A method comprising, in at least one vessel of a plurality of vessels, the at least one vessel comprising an immune cell and a first and second solid support, wherein the immune cell comprises an immunoglobulin heavy chain (IgH) mRNA and an immunoglobulin light chain (IgL) mRNA, and wherein:
(i) the first solid support comprises a polynucleotide comprising a barcode, a first forward primer binding sequence, and a first reverse primer binding sequence; and the second solid support comprises a polynucleotide complementary to at least a portion of the IgH mRNA and a polynucleotide complementary to at least a portion of the IgL mRNA;
(ii) the first solid support comprises (1) a polynucleotide comprising a barcode, a first forward primer binding sequence, and a first reverse primer binding sequence, and (2) a polynucleotide complementary to at least a portion of the IgH mRNA; and the second solid support comprises a polynucleotide complementary to at least a portion of the IgL mRNA;
(iii) the first solid support comprises a polynucleotide complementary to at least a portion of the IgH mRNA; and the second solid support comprises a (1) a polynucleotide comprising a barcode, a first forward primer binding sequence, and a first reverse primer binding sequence, and (2) a polynucleotide complementary to at least a portion of the IgL mRNA; or
(iv) the first solid support comprises a polynucleotide complementary to at least a portion of the IgH mRNA; the second solid support comprises a polynucleotide complementary to at least a portion of the IgL mRNA; and the at least one vessel of the plurality of vessels further comprises a polynucleotide comprising a barcode, a first forward primer binding sequence, and a first reverse primer binding sequence:
(a) reverse transcribing the IgH and IgL mRNAs to form IgH and IgL cDNAs, wherein the IgH cDNA comprises a nucleic acid encoding a heavy chain variable region (VH) and the IgL cDNA comprises a nucleic acid encoding a light chain variable region (VL); wherein the IgH and IgL cDNAs comprise a second forward primer binding sequence and a sequence complementary to the first reverse primer binding sequence; and
(b) amplifying the IgH and IgL cDNAs, wherein the barcode is added to the IgH and IgL cDNAs using a first primer complementary to the first forward primer binding sequence, a second primer complementary to the second forward primer binding sequence, and a third primer complementary to the first reverse primer binding sequence;
wherein the method further comprises:
(c) sequencing the amplified barcoded IgH and IgL cDNAs, wherein sequencing the amplified barcoded IgH cDNAs occurs simultaneously with sequencing the amplified barcoded IgL cDNAs.
8. The method of claim 7 , further comprising selecting an antibody candidate based on:
(a) total quantity of two or more individually paired VH and VL sequences, and
(b) variance of the VH and/or VL sequence from a corresponding germ line sequence.
9. The method of claim 7 , wherein the immune cell is a leukocyte, B-cell, or T-cell.
10. The method of claim 7 , wherein the immune cell is a memory B-cell.
11. The method of claim 8 , further comprising screening the selected antibody for functional specificity, affinity, and/or neutralization ability.
12. The method of claim 8 , further comprising evolving the selected antibody by directed evolution.
13. A method comprising, in at least one vessel of a plurality of vessels, the at least one vessel comprising (i) an immune cell comprising an immunoglobulin heavy chain (IgH) mRNA and an immunoglobulin light chain (IgL) mRNA; (ii) a first solid support comprising a polynucleotide complementary to at least a portion of the IgH mRNA; (iii) a second solid support comprising a polynucleotide complementary to at least a portion of the IgL mRNA; and (iv) a third solid support comprising a polynucleotide comprising a barcode, a first forward primer binding sequence, and a first reverse primer binding sequence:
(a) reverse transcribing the IgH and IgL mRNAs to form IgH and IgL cDNAs, wherein the IgH cDNA comprises a nucleic acid encoding a heavy chain variable region (VH) and the IgL cDNA comprises a nucleic acid encoding a light chain variable region (VL); wherein the IgH and IgL cDNAs comprise a second forward primer binding sequence and a sequence complementary to the first reverse primer binding sequence; and
(b) amplifying the IgH and IgL cDNAs, wherein the barcode is added to the IgH and IgL cDNAs using a first primer complementary to the first forward primer binding sequence, a second primer complementary to the second forward primer binding sequence, and a third primer complementary to the first reverse primer binding sequence;
wherein the method further comprises:
(c) sequencing the amplified barcoded IgH and IgL cDNAs, wherein sequencing the amplified barcoded IgH cDNAs occurs simultaneously with sequencing the amplified barcoded IgL cDNAs.
14. The method of claim 13 , further comprising selecting an antibody candidate based on:
(a) total quantity of two or more individually paired VH and VL sequences, and
(b) variance of the VH and/or VL sequence from a corresponding germ line sequence.
15. The method of claim 13 , wherein the immune cell is a leukocyte, B-cell, or T-cell.
16. The method of claim 13 , wherein the immune cell is a memory B-cell.
17. The method of claim 14 , further comprising screening the selected antibody for functional specificity, affinity, and/or neutralization ability.
18. The method of claim 14 , further comprising evolving the selected antibody by directed evolution.